Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Stock Chart & Stats
$82.02
-$0.34(-2.31%)
At close: 4:00 PM EST
$82.02
-$0.34(-2.31%)
Day’s Range― - ―
52-Week Range$16.65 - $114.69
Previous CloseN/A
Volume11.83K
Average Volume (3M)239.96K
Market Cap
$936.74M
Enterprise Value$917.60M
Total Cash (Recent Filing)$63.57M
Total Debt (Recent Filing)$16.02M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Apr 06, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding11,836,490
10 Day Avg. Volume329,512
30 Day Avg. Volume239,959
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-2.46
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-48.01
Forecast
1Y Price Target
$176.73Price Target Upside115.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesA clear, baseline‑controlled Phase 3 SELVA design with standardized photography and conservative success criteria could produce convincing efficacy data that positions the therapy as a best‑in‑class topical option for the targeted condition.
Market Adoption And Unmet NeedA large patient population with no approved therapies, strong physician enthusiasm for a high‑concentration topical product, and a concentrated prescriber base support the potential for rapid adoption and meaningful commercial upside.
Regulatory StrategySenior FDA engagement together with planned Breakthrough Therapy filings increases the chance of accelerated review and may allow single‑arm pivotal designs that shorten development timelines and reduce regulatory uncertainty.
Bears Say
Clinical Response Variability And Execution RiskPrior studies showing a subset of nonresponders to topical statins, combined with reliance on enabling studies and regulatory alignment to advance programs, raise development and approval execution risk.
Financing And Cash RunwaySignificant cash burn and a limited cash runway increase the likelihood of near‑term fundraising, which could dilute shareholders and create heightened stock volatility if additional capital is required.
Formulation And DeliveryThe rapamycin molecule's poor solubility, instability, and limited skin penetration pose meaningful formulation hurdles that could impede achieving consistent clinical performance and complicate regulatory review.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $16.65 and its highest was $114.69 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $936.74M.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 50 days.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on Nov 11, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.838 by -$0.192.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate is -0.91.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 11,836,490 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.838. Following the earnings report the stock price went down -3.039%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$176.73 (115.47% Upside)
$176.73 (115.47% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 252.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 3.5%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
390.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
226.17%
Trailing 12-Months
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q3 2025
0:00 / 0:00
PVLA Stock 12 Month Forecast
Average Price Target
$176.73
▲(115.47% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
1.83% Insiders
5.71% Mutual Funds
45.35% Other Institutional Investors
37.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---